Skip to main navigation

Contact
Info
CRISPR/Cas9
Programs
& Pipeline
Patients
& Families
Healthcare
Professionals
Investors
& Media
Careers

Investors & Media

Investors

Investor Relations

Investors & Media
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Analyst Coverage
Investor FAQs
Information Request
IR & Media Contacts

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

–

Nov 11, 2020

Summary Toggle Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Events & Presentations

There are currently no upcoming events.

Info

Overview
Leadership
Partners

Healthcare Professionals

Overview

CRISPR/Cas9

What’s CRISPR/Cas9?
How CRISPR/Cas9 Works
Types of Edits
Glossary

Investors & Media

Overview
Press Releases
Scientific Publications & Presentations
Corporate Deck
Events & Presentations
Press Kit

Programs & Pipeline

Our Full-Spectrum Approach
Pipeline
In Vivo Therapies
Ex Vivo Therapies

Careers

Overview

Patients & Families

Our Commitment
Clinical Trials
Community Perspective & Resources
Expanded Access Policy

© Intellia Therapeutics 2020

Cookie Policy
Terms of Use
Privacy Policy

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.